Liver transplantation program at the Burnasyan Federal Biophysical Center: experience in 500 procedures

• Published in: Hirurgija (Moskva) no. 7; p. 45
• Main Authors: Voskanyan, S E, Sushkov, A I, Artemiev, A I, Rudakov, V S, Kolyshev, I Yu, Gubarev, K K, Zabezhinskiy, D A, Popov, M V
• Format: Journal Article
• Language: English; Russian
• Published: Russia (Federation) 2024
• Subjects: Adult; Female; Humans; Liver Transplantation - adverse effects; Liver Transplantation - methods; Liver Transplantation - statistics & numerical data; Living Donors - statistics & numerical data; Male; Middle Aged; Registries - statistics & numerical data; Russia - epidemiology; Survival Rate - trends; Waiting Lists; Russia; immunosuppression; deceased donor; living-related donor; liver cirrhosis; liver transplantation; survival
• ISSN: 0023-1207
• DOI: 10.17116/hirurgia202407145

To analyze the features and outcomes of 500 liver transplantations in adults over a 12-year period. The study included data on 500 liver transplantations between May 2010 and April 2023. We analyzed 483 adults who underwent transplantation and 438 candidates for this procedure. All data were obtained from local liver transplantation registry. Clinical outcomes were recorded as of June 1, 2023. Statistical analysis was performed using the Statistica 12 (StatSoft Inc., USA) and Jamovi version 2.3.21.0 software (Jamovi project). Among 438 patients in the waiting list between January 2012 and May 2023, liver transplantation was performed in 198 (45%) cases including 27 (6%) transplantations from living-related donors and 37 (8%) procedures in other centers. There were 109 (25%) deaths. The 1- and 3-year survival rates were 81% (95% CI 76-85%) and 50% (95% CI 42-59%), respectively. Organs from deceased donors ( =134, 27%) and living-related donors ( =366, 73%) were used for transplantations. Redo transplantations were necessary in 21 (4%) cases. The median age of recipients was 45 years (range 18-72), median MELD-Na score - 16 (range 6-43). The most common indications for transplantation were viral cirrhosis (37%), cholestatic liver disease (16%), and hepatocellular carcinoma (14%). Monotherapy with calcineurin inhibitors was performed in 39% of cases, combination of calcineurin inhibitors and glucocorticoids, antimetabolites or mTOR inhibitors - 52%, three-component schemes - 8% of cases. Annual, 5- and 7-year survival rates of recipients after primary transplantation were 87% (95% CI: 84-90%), 79% (95% CI: 75-83%) and 75% (95% CI: 70-80%), respectively. In case of liver transplantation from living-related donors, these values were 89% (95% CI: 86-92%), 84% (95% CI: 80-88%) and 80% (95% CI: 75-85%), after transplantation from deceased donors - 81% (95% CI: 74-88%), 66% (95% CI: 57-76%) and 58% (95% CI: 45-72%), respectively. Liver transplantation is highly effective for patients with diffuse and focal liver diseases. Living donors not only significantly improve availability of this technology, but also provide substantial advantages in outcomes compared to liver transplantation from deceased donors, reducing the likelihood of recipient mortality by 10% after one post-transplantation year and by more than 20% after five years.